AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02201849
Drug: Study Drug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02201849
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03643575
Drug: Vicks Cough Syrup for Chesty Coughs
RxNorm normalized name: Vicks Cough Syrup for Chesty Coughs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicks Cough Syrup for Chesty Coughs 15 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water
Trial: NCT03643575
Drug: Robitussin Extra Strength Chest Congestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robitussin Extra Strength Chest Congestion 5 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water
Trial: NCT03643575
Drug: Organ-I- NR tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Organ-I- NR tablet (containing 200 mg guaifenesin) with 240 mL of water
Trial: NCT00041574
Drug: Inhaled Nitric Oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Nitric Oxide will be delivered through the INOpulse® at a Low Dose Range (3mL to 10mL; in 1mL increments) and Ultra Low Dose Ranges (0.5mL to 4mL; 0.5mL, then 1 to 4mL in 1mL increments).
Trial: NCT02324972
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01958281
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s) administered orally once daily
Trial: NCT01958281
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90/400 mg fixed-dose combination (FDC) tablet administered orally once daily
Trial: NCT00390312
Drug: Intranasal Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal placebo
Trial: NCT00390312
Drug: Intravenous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous placebo
Trial: NCT00179465
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01000402
Drug: Psychopharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (according to response, serum levels, and tolerance) 150-1500mg Valproate (according to response, serum levels, and tolerance) 125-2000mg Risperidone (according to response, and tolerance)0.5-6mg Olanzapine(according to response, and tolerance)2.5-20mg Ziprasidone(according to response, and tolerance)40-160mg Topiramate (according to response, and tolerance)25-300mg Quetiapine (according to response, and tolerance)25-500mg Aripiprazole (according to response, and tolerance)5-20mg Lamotrigine (according to response, and tolerance)25-200mg Fluoxetine (according to response, and tolerance) 1-40mg Sertraline (according to response, and tolerance)25-200mg Methylphenidate (according to weight, response, and tolerance)0.3 -0.7mg/kg/day
Trial: NCT03127631
Drug: Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prescription for a low to moderate dose statin, such as simvastatin 10-40mg daily, atorvastatin 10-40mg daily, rosuvastatin 5-20mg daily or pravastatin 10-40mg daily.
Trial: NCT03127631
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription for an ACE-I (preferable) or an angiotensin receptor blocker for baseline systolic blood pressure greater \>130mmHg, or other blood pressure lowering medication as applicable.
Trial: NCT03517137
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For PET positive (score of 4-5 following Deauville Criteria) patients: Cyclophosphamide is administered as an IV infusion over a period of 30 minutes at 1250 mg/m² on day 2, every 3 weeks (6 cycles)
Trial: NCT00153088
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00135707
Drug: Dietary Supplement/Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1000 mg) and Vitamin E (400 IU) per capsule, two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.
Trial: NCT04481971
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT04481971
Drug: lactose in capsules gelatin
RxNorm normalized name: lactose Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT04299854
Drug: Dinoprostone 10mg
RxNorm normalized name: DINOPROSTONE 10MG INSERT,VAG
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vaginal delivery system containing 10mg of dinoprostone placed at the bottom of the vagina
Trial: NCT02337933
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcined magnesia capsules of 150 mg, once a day before breakfast
Trial: NCT00303745
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00765700
Drug: Topical Ketoprofen 10% Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Administration
Trial: NCT00765700
Drug: Topical Placebo Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Administration
Trial: NCT00032162
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20/30/40 mg/qm q4w Dose finding study
Trial: NCT01555320
Drug: Qishen Yiqi Dripping Pills
RxNorm normalized name: DRIP COLLECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One packet of Qishen Yiqi Dripping Pills (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
Trial: NCT01555320
Drug: Qishen Yiqi dripping pills dummy
RxNorm normalized name: Caltrate Gummy Bites Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One packet of Qishen Yiqi Dripping Pills dummy (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
Trial: NCT01829464
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-875 placebo-matching tablets
Trial: NCT04137627
Drug: Melatonin 20 MG Oral Capsule
RxNorm normalized name: melatonin 20 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The administration of Melatonin 20 mg in addition to neoadjuvant chemotherapy to observe the antioxidant and onco-static effect.
Trial: NCT04137627
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The administration of placebo capsule in addition to neoadjuvant chemotherapy
Trial: NCT02248701
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive placebo (weekly) by intramuscular injection
Trial: NCT02248701
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive placebo pill (daily) orally
Trial: NCT02053870
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with daily medication prescribed by the physician, during 3 weeks.
Trial: NCT00963222
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 cap placebo/day for 3 month
Trial: NCT03870100
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: water injection Route of administration: subcutaneous
Trial: NCT02207309
Drug: Placebo (for Pazopanib)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04322175
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meloxicam Eye Drops
Trial: NCT01645306
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single intravenous injection
Trial: NCT00810368
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcrystalline cellulose placebo tablets x2 daily
Trial: NCT02747875
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The treatment phase will begin at the induction of general anesthesia and finish at the end of the surgical procedure. Under the direction of the cardiac anesthesiologist subjects will be premedicated and general anesthesia will be induced with standard anesthetic monitoring and management. Participants will receive 20 mcg/kg of fentanyl prior to surgical incision, over 20 minutes. General anesthesia will be maintained with inhalational anesthetics and paralytics. The subject will continue to be evaluated for hemodynamic stability, bleeding, and respiratory effort. The postoperative intensive care phase will begin at time of room admission and end at day three of hospital stay. All subjects will receive morphine or oxycodone analgesics and sedation medication based on the hospital's postoperative pain control and agitation protocol. Standard electronic documentation will be maintained throughout and include: medications, vital signs, and events.
Trial: NCT01694485
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to abrilumab administered by subcutaneous injection
Trial: NCT00506909
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 IU BID or 40 IU BID
Trial: NCT01495377
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Powder for injection/ infusion fluid solution, 1 mg Infusion TCI 3 ng/ml 60 min ( 0,15 ug/kg/min)
Trial: NCT01495377
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion fluid, solution 9 mg/ml ( hydrogenic solution )
Trial: NCT03172780
Drug: Diclofenac sodium gel 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
Trial: NCT03172780
Drug: Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
Trial: NCT03172780
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Gel 4 gm, 4 times a day for 4 weeks
Trial: NCT00538291
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00268788
Drug: Subcutaneous immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individually dosed, given twice a week.
Trial: NCT01696695
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: First line capecitabine based oral tablet treatment in line with the effective Summary of Product Characteristics
Trial: NCT01696695
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First line chemotherapy according to effective official Summary of Product Characteristics. The study protocol does not specify any particular therapy.
Trial: NCT03570697
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo subcutaneous monthly.
Trial: NCT03570697
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-intensity statin treatment with atorvastatin ≥ 40 mg daily or equivalent as background therapy~Investigators will up-titrate statin therapy to the maximally tolerated dose, in accordance with local guidelines, prior to randomization.
Trial: NCT00766025
Drug: Rosuvastatin Calcium
RxNorm normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single oral dose on days 1, 4, 5, 6, 10-16, 17
Trial: NCT04633733
Drug: HL237 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HL237 400mg will be administered orally twice a day.
Trial: NCT03070366
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * cisplatin~* 5FU~* carboplatin~* cetuximab
Trial: NCT02583542
Drug: AZD2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD2014 is a dual inhibitor of both mTORC1 (rapamycin-sensitive) and mTORC2 (rapamycin insensitive); compared to rapalogues, AZD2014 has a broader range of growth inhibitory activity in preclinical models based on a more profound mTORC1 inhibition and the additional inhibition of mTORC2. AZD2014 is currently in phase 2 studies in renal cell cancers and metastatic breast cancer.
Trial: NCT02583542
Drug: AZD6244
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib (AZD6244, ARRY-142886) is an orally available, potent, selective, non-ATP competitive inhibitor of MEK1/MEK2 kinases. Selumetinib has demonstrated clinical efficacy in pre-treated KRAS-mutant NSCLC, leading to a significantly improved progression-free survival in combination with docetaxel compared to docetaxel alone.
Trial: NCT03208127
Drug: Treatment with Direct Acting Antiviral tablet
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV Treatment for 12 Weeks
Trial: NCT02837146
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction and maintenance phase: Methotrexate 15-20 mg/week from baseline to week 54
Trial: NCT02746263
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02040766
Drug: Placebo BAI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was delivered by a single inhalation using a breath-actuated inhaler (BAI) twice each day.
Trial: NCT02040766
Drug: Placebo MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was delivered by a single inhalation using a metered-dose inhaler (MDI) twice each day.
Trial: NCT04541719
Drug: Patient-controlled remifentanil analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient controlled remifentanil analgesia with a regimen to provide a bolus of 40 μg remifentanil with a lockout interval of 2 min
Trial: NCT03585062
Drug: S1,
RxNorm normalized name: Vaccine product containing only S, preS1, preS2 Hepatitis B virus recombinant surface antigens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 is a combination of tegafur, gimeracil and oteracil at a molar ratio of 1:0.4:1, and is a new oral fluoropyrimidine anticancer agent shown to be effective for pancreatic cancer. cancer
Trial: NCT02974114
Drug: Paracetamol and caffeine
RxNorm normalized name: codeine and paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test product containing 500 mg paracetamol and 65 mg caffeine
Trial: NCT03855228
Drug: Placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of placebo administered as a nasal spray for 15 days.
Trial: NCT03855228
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of placebo administered as an oral tablet for 15 days.
Trial: NCT04462770
Drug: EPX-100 (clemizole HCl)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of EPX-100
Trial: NCT04462770
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of placebo
Trial: NCT01443208
Drug: desvenlafaxine
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one 50 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days
Trial: NCT01443208
Drug: desvenlafaxine
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one 100 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days
Trial: NCT01443208
Drug: desvenlafaxine
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: two 100 mg desvenlafaxine succinate sustained-release tablets or matching placebo, single dose and once daily dose for 5 days
Trial: NCT00816959
Drug: R-mabHDI and ABVD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will receive R-mabHDI intravenously, separately for about 7 hours on days 1,8,15 and 22 (once a week) of every cycle. Each cycle is 4 weeks. R-mabHDI will be given for 2 cycles.~Also the subjects will receive the ABVD combination intravenously for about 1 hour on day 1 and 15 of every cycle (every 2 weeks). Each cycle is 4 weeks. ABVD will be given for 6 cycles.
Trial: NCT00914888
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subject with cIAI:~Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered.
Trial: NCT00914888
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subject with CAP:~IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).
Trial: NCT01358045
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Application on the lesion 2 times a day 8 weeks.
Trial: NCT00244322
Drug: LY450139 dihydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00244322
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01128842
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1500 mg/m\^2 twice daily by mouth.
Trial: NCT00319501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular autoinjector; administered at onset of an episode
Trial: NCT00427128
Drug: fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg/day increased over 12 weeks to 20-80 mg/day; 20-80 mg/day maintained from week 13-36.
Trial: NCT00427128
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Week 13-36.
Trial: NCT00617461
Drug: GEn 1200mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200mg/day gabapentin enacarbil
Trial: NCT00617461
Drug: GEn 3600mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3600mg/day gabapentin enacarbil
Trial: NCT00650299
Drug: Xanax XR® Tablets 3 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mg, single dose fed
Trial: NCT03784261
Drug: Drug: Salirumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To examine the effects of salirumab in RA patients
Trial: NCT03784261
Drug: Drug: Tocilizmab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To examine the effects of tocilizmab in RA patients
Trial: NCT03402893
Drug: ONEXTON Topical Gel
RxNorm normalized name: Onexton Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onexton gel applied once daily to face
Trial: NCT00803842
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline (the study drug) will be provided to all subjects as 100 mg tablets. They will be allocated enough doxycycline to last them until their next scheduled visit. The doxycycline tablets should be taken orally (only) at a dosage of 100 mg every 12 hours. Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration. The doxycycline tablets should not be taken with foods that contain calcium. The absorption of doxycycline is reduced when taking bismuth subsalicylate. Duration of study period if 14 days
Trial: NCT05491720
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo tablet (Galenus pharmaceutical company)
Trial: NCT00795145
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous, Placebo control for blinding, Normal Saline, Single dose
Trial: NCT00981201
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Months 1-3:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)
Trial: NCT00981201
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Months 4-6:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)
Trial: NCT00981201
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Months 1-3:~By mouth twice daily.